natgillin/translations-raw huggingface dataset:
The system of claim 17, further comprising a flow measurement and control system for controlling the coker recycle fraction (25) to be from about 15 weight percent to about 25 weight percent of the coker feed mixture (39). The system of claim 17, further comprising: 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da nadalje obuhvaća sustav za mjerenje i kontrolu protoka za kontrolu frakcije recikliranja kokera (25) koja treba biti od oko 15 težinskih postotaka do oko 25 težinskih postotaka smjese za punjenje kokera (39).
The system of claim 17, further comprising an operating system configured to control the residuum hydroconversion reactor system (13) to produce the mixed heavy hydrocarbon fraction (35) having a nickel content of less than about 70 ppmw, a vanadium content of less than about 70 ppmw, an asphaltenes/Conradson Carbon Residue (CCR) ratio of less than 0.7 to 1, and a total sulfur content of less than about 24,000 ppmw. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da nadalje sadržava operativni sustav konfiguriran za kontrolu reaktorskog sustava rezidualne hidrokonverzije (13) za proizvodnju miješane teške ugljikovodične frakcije (35) koja ima sadržaj nikla manji od oko 70 ppmw, sadržaj vanadija manje od oko 70 ppmw, omjer asfalten / Conradson ugljični ostatak (CCR) manji od 0,7 do 1, i ukupni sadržaj sumpora manji od oko 24,000 ppmw.
The system of claim 17, wherein the residuum hydroconversion reactor system (13) comprises a slurry-phase hydrocracking process. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da reaktorski sustav rezidualne hidrokonverzije (13) obuhvaća postupak hidrokrekinga u suspenzijskoj fazi.
The system of claim 17, wherein the hydroconversion reactor (94) comprises a fixed-bed VGO hydrocracking reactor system, a fluidized bed VGO hydrocracking reactor system. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da reaktor za hidrokonverziju (94) sadržava reaktorski sustav za hidrokrekiranje VGO s fiksnim slojem i hidrokreking reaktorski sustav za hidrokrekiranje VGO s fluidiziranim slojem.
The conjugate according to any one of claims 1 to 6, wherein the conjugate has anti-obesity effects. 
Konjugat prema bilo kojem od zahtjeva 1 do 6, naznačen time da konjugat ima učinak protiv pretilosti.
The conjugate according to claim 12, wherein the reactive group is selected from an aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group, or a succinimide derivative. 
Konjugat prema zahtjevu 12, naznačen time da je reaktivna skupina odabrana iz aldehidne skupine, propionaldehidne skupine, butiraldehidne skupine, maleimidne skupine ili derivata sukcinimida.
The conjugate according to claim 12, wherein the reactive groups at both ends are the same as or different from each other. 
Konjugat prema zahtjevu 12, naznačen time da su reaktivne skupine na oba kraja iste ili različite jedna od druge.
The conjugate according to any one of claims 1 to 16, wherein the immunoglobulin Fc region is a derivative in which a region capable of forming a disulfide bond is deleted, certain amino acid residues are eliminated at the N-terminal end of a native Fc form, a methionine residue is added at the N-terminal end of a native Fc form, a complement-binding site is deleted, or an antibody dependent cell mediated cytotoxicity (ADCC) site is deleted. 
Konjugat prema bilo kojem od zahtjeva 1 do 16, naznačen time da je Fc regija imunoglobulina derivat u kojem se regija koja može oblikovati disulfidnu vezu briše, određeni ostatci aminokiseline se uklanjaju na N-terminalnom kraju urođenog Fc oblika, ostatak metionina se dodaje na N-terminalni kraj urođenog Fc oblika, mjesto vezivanja komplementa se briše ili se briše mjesto stanične citotoksičnosti ovisne o protutijelima (ADCC).
A pharmaceutical composition for the prevention or treatment of obesity, comprising the conjugate of any one of claims 1 to 17. 
Farmaceutski sastav za prevenciju ili liječenje pretilosti, koji sadrži konjugat prema bilo kojem od zahtjeva 1 do 20.
The pharmaceutical composition according to claim 21, further comprising a pharmaceutically acceptable carrier. 
Farmaceutski sastav prema zahtjevu 21, koji nadalje sadrži farmaceutski prihvatljiv nosač.
The pharmaceutical composition according to claim 18 or 19, wherein the composition is administered alone or in combination with other pharmaceutical formulations showing prophylactic or therapeutic effects on obesity. 
Farmaceutski sastav prema zahtjevu 21 ili 22, naznačen time da se sastav primjenjuje sam ili u kombinaciji s drugim farmaceutskim formulacijama koje pokazuju profilaktičke ili terapeutske učinke na pretilost.
The pharmaceutical composition according to any one of claims 21 to 23, wherein the pharmaceutical formulation is a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a β3A receptor agonist, an amylin receptor agonist, a ghrelin antagonist, or a ghrelin receptor antagonist. 
Farmaceutski sastav prema bilo kojem od zahtjeva 21 do 23, naznačen time da je farmaceutska formulacija agonist GLP-1 receptora, agonist leptinskog receptora, DPP-IV inhibitor, antagonist Y5 receptora, antagonist receptora melanin koncentrirajućeg hormona (MCH), agonist Y2/3 receptora, agonist MC3/4 receptora, inhibitor želučane/gušteračne lipaze, agonist 5HT2c, agonist β3A receptora, agonist receptora amilina, antagonist grelina ili antagonist receptora grelina.
an inverse scanning module configured to convert the quantization coefficient information into a two-dimensional quantization block; 
modul za inverzno skeniranje konfiguriran da konvertira informacije o koeficijentu kvantizacije u dvodimenzionalni kvantizacijski blok;
The method of claim 1, wherein the antibody is derived from mammals, preferably from human, mice or rats. 
Postupak prema zahtjevu 1, naznačen time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa ili štakora.
The method of claim 1, wherein the antibody is selected from the group consisting of IgG, IgA, IgE, IgD, and IgM. 
Postupak prema zahtjevu 1, naznačen time što je antitijelo odabrano iz skupine koja se sastoji od IgG, IgA, IgE, IgD i IgM.
The mixture of claim 7, wherein the antibody is derived from mammals, preferably from human, mice or rats. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa ili štakora.
The mixture of claim 7, wherein the antibody is selected from the group consisting of IgG, IgA, IgE, IgD, and IgM. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo odabrano iz skupine koja se sastoji od IgG, IgA, IgE, IgD i IgM.
The compound for use according to claim 11, wherein the ammonia-lowering compound is selected from the group consisting of rifaximin, lactulose, ornithine phenylacetate and glycerol phenyl butyrate. 
Spoj za upotrebu prema zahtjevu 11, naznačen time što je spoj koji snižava količinu amonijaka odabran iz skupine koja se sastoji od rifaksimina, laktuloze, ornitin fenilacetata i glicerol fenil butirata.
The compound for use according to claim 11 or claim 12, wherein the ammonia-lowering compound is selected from the group consisting of rifaximin and lactulose. 
Spoj za upotrebu prema zahtjevu 11 ili zahtjevu 12, naznačen time što je spoj koji snižava količinu amonijaka odabran iz skupine koja se sastoji od rifaksimina i laktuloze.
An aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. 
Vodeni farmaceutski sastav za parenteralnu primjenu koji sadrži tapentadol ili njegovu fiziološki prihvatljivu sol, naznačen time što je koncentracija tapentadola unutar raspona od 0,10 do 8,00 mg/mL, temeljeno na masi slobodne baze tapentadola i temeljeno na ukupnom obujmu sastava; i pri čemu je pH vrijednost sastava puferirana i unutar raspona od 4,0 do 6,0.
The composition according to any of the preceding claims, wherein the pH value is within the range of from 4.5 to 5.5, in particular before and after autoclaving. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time što je pH vrijednost unutar raspona od 4,5 do 5,5, posebice prije i poslije autoklaviranja.
The composition according to any of the preceding claims, which comprises a buffer comprising one or more conjugate bases and one or more conjugate acids selected from the group consisting of citrate, hydrogencitrate, dihydrogencitrate and citric acid. 
Sastav prema bilo kojem od prethodnih zahtjeva, koji sadrži pufer koji sadrži jednu ili više baza konjugata i jednu ili više kiselina konjugata odabranih iz skupine koja se sastoji od citrata, hidrogencitrata, dihidrogencitrata i limunske kiseline.
The composition according to any of the preceding claims, wherein the concentration of Tapentadol is within the range of 1.0±0.5 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time što je koncentracija tapentadola unutar raspona od 1,0±0,5 mg/mL, temeljeno na masi slobodne baze tapentadola i temeljeno na ukupnom obujmu sastava.
The composition according to any of the preceding claims, which comprises an isotonizing agent. 
Sastav prema bilo kojem od prethodnih zahtjeva, koji sadrži agens za izotoniziranje.
The composition according to any of the preceding claims, which comprises Tapentadol in an amount within the range of from 1.00 mg to 3.00 mg, based on the weight of Tapentadol free base. 
Sastav prema bilo kojem od prethodnih zahtjeva, koji sadrži tapentadol u količini unutar raspona od 1,00 mg do 3,00 mg, temeljeno na masi slobodne baze tapentadola.
The composition according to any of the preceding claims for use in the treatment of pain. 
Sastav prema bilo kojem od prethodnih zahtjeva za uporabu u liječenju boli.
The composition for use according to claim 8, wherein the pain is treated in mammals. 
Sastav za uporabu prema zahtjevu 8, naznačen time što se bol liječi kod sisavaca.
The composition for use according to claim 9, wherein the mammals are humans. 
Sastav za uporabu prema zahtjevu 9, naznačen time što su sisavci ljudi.
The composition for use according to claim 10, wherein the humans are pediatric patients. 
Sastav za uporabu prema zahtjevu 10, naznačen time što su ljudi pedijatrijski pacijenti.
The composition for use according to claim 11, wherein the pediatric patients are newborn infants. 
Sastav za uporabu prema zahtjevu 11, naznačen time što su pedijatrijski pacijenti novorođenčad.
The composition for use according to claim 12, wherein the pediatric patients are premature infants. 
Sastav za uporabu prema zahtjevu 12, naznačen time što su pedijatrijski pacijenti nedonoščad.
The composition for use according to any of claims 8 to 13, wherein the composition is administered by injection or infusion. 
Sastav za uporabu prema bilo kojem od zahtjeva 8 do 13, naznačen time što je sastav primijenjen injekcijom ili infuzijom.
A container comprising the pharmaceutical composition according to any of the preceding claims. 
Spremnik koji sadrži farmaceutski sastav prema bilo kojem od prethodnih zahtjeva.
wherein said coupling means are configured for allowing a rotational actuation movement of the step board (11) about an axis of rotation (12); 
pri čemu su navedena sredstva za spajanje konfigurirana za dozvoljavanje rotacijskog aktivacijskog kretanja gazišta (11) stepenice oko osi (12) rotacije;
wherein said step board (11) exhibits a planar configuration which, in the extracted position, defines a supporting surface that is walkable by the operator and wherein said axis of rotation (12) is substantially perpendicular to said step board (11); 
pri čemu navedeno gazište (11) stepenice pokazuje planarnu konfiguraciju koja, u izvučenom položaju, definira potpornu površinu po kojoj operater može hodati i pri čemu je navedena os (12) rotacije u suštini normalna na navedeno gazište (11) stepenice;
wherein the machine comprises actuation means (17) operatively associated to said step board (11) and suitable for imposing said actuation movement to the step board (11) via which said step board is brought from the retracted position to the extracted position thereof in conjunction with the opening of the maneuver cab's access door and from the extracted position to the retracted position thereof in conjunction with the closing of the maneuver cab's access door (8); 
pri čemu radni stroj sadrži sredstva (17) za aktivaciju operativno povezana za navedeno gazište (11) stepenice i pogodna za nametanje navedenog aktivacijskog kretanja gazištu (11) stepenice putem kojeg se navedeno gazište stepenice dovodi iz njegovog uvučenog položaja u izvučen položaj, u vezi sa otvaranjem vrata za pristup kabine za upravljanje i iz njegovog izvučenog položaja u uvučen položaj, u vezi sa zatvaranjem vrata (8) za pristup kabine za upravljanje;
A self-propelled working machine according to claim 3 and claim 4, wherein said axis of rotation (12) is arranged in a radially inner portion of the step board (11). 
Radni stroj na vlastiti pogon u skladu sa patentnim zahtjevom 3 i patentnim zahtjevom 4, pri čemu je navedena os (12) rotacije postavljena u radijalno unutrašnjem dijelu gazišta (11) stepenice.
The pharmaceutical composition according to claim 20, wherein the pharmaceutical formulation is selected from the group consisting of a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2C agonist, a β3A receptor agonist, an amylin receptor agonist, a ghrelin antagonist, and a ghrelin receptor antagonist. 
Farmaceutski sastav prema bilo kojem od zahtjeva 21 do 23, naznačen time da je farmaceutska formulacija agonist GLP-1 receptora, agonist leptinskog receptora, DPP-IV inhibitor, antagonist Y5 receptora, antagonist receptora melanin koncentrirajućeg hormona (MCH), agonist Y2/3 receptora, agonist MC3/4 receptora, inhibitor želučane/gušteračne lipaze, agonist 5HT2c, agonist β3A receptora, agonist receptora amilina, antagonist grelina ili antagonist receptora grelina.
The edging strip as claimed in claim 1, characterized in that the thickness of the edging strip is in the range of about 0.3 to 4 mm, and visible upper side of the edging strip has been laminated with a plastics foil or with a metal foil, and/or has been embossed and/or printed and/or coated. The edging strip as claimed in claim 1 having bulk patterning. 
Rubna traka prema jednom od prethodnih zahtjeva, naznačena time, što debljina rubne trake poželjno leži u opsegu od 0,3 do 4 mm i što je vidljivi gornji sloj laminiran i/ili otisnut i/ili lakiran i/ili obložen plastičnom odnosno metalnom folijom i/ili što je sloj taljevine nakon postavljanja rubne trake na ploču materijala od drveta, naročito ploču za nameštaj, ima preostalu debljinu od >0,02 mm, poželjno >0,05 mm.
The edging strip as claimed in claim 1, characterized in that an adhesion promoter is present the melt layer and is composed of a liquid mixture comprising water and/or organic solvents, binders and mineral fillers. 
Rubna traka prema jednom od prethodnih zahtjeva, naznačena time što je sloj taljevine osiguran s posrednikom za vezanje, koji se sastoji od tekuće mješavine tvari koje kao glavne komponente sadrže vodu i/ili organska otapala, vezivna sredstva kao i mineralna punila.
A process for synthesing hydrocarbons, comprising the steps of: formulating a hydrogen lean syngas stream in a non-catalytic partial oxidation reaction; 
Postupak sinteze ugljikovodika, naznačen time što se sastoji u koracima: formuliranja struje sinteznog plina siromašne vodikom reakcijom nekatalitičke djelomične oksidacije;
The process characterized in claim 2, wherein said gasifier gasifies a member selected from the group consisting of coal, biomass, petroleum resids, petcoke, municipal waste, plastics, wood waste, demetallized tire scrap, forestry waste material, waste water biomass, sewage biomass, agricultural waste, agricultural byproducts, carbonaceous material and mixtures thereof. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što navedeni toplinski rasplinjač rasplinjava člana kojeg se bira iz skupine koju čine ugljen, biomasa, naftni ostaci, naftni koks, komunalni otpad, plastika, drvni otpad, demetalizirani ostaci autoguma, šumarski otpadni materijal, biomasa iz otpadne vode, biomasa iz kanalizacije, poljoprivredni otpad, poljoprivredni nusproizvodi, ugljični materijal i njihove smjese.
The compound of claim 1, wherein Y is CH2. 
Spoj prema zahtjevu 1, pri čemu Y je CH2.
The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the pharmaceutical composition of claim 6 for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj prema bilo kojem od patentnih zahtjeva 1 – 4, ili njegova farmaceutski prihvatljiva sol, solvat, ili stereoizomer, ili farmaceutski pripravak prema zahtjevu 6 za upotrebu u postupku za liječenje, vođenje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, poremećaj imunodeficijencije, poremećaji SŽS, ozljede SŽS, ateroskleroza ili srodni poremećaj, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
The compound of claim 5, or a pharmaceutically acceptable salt or stereoisomer thereof, or the pharmaceutical composition of claim 7 for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj prema zahtjevu 5, ili njegova farmaceutski prihvatljiva sol ili stereoizomer, ili farmaceutski pripravak prema zahtjevu 7 za upotrebu u postupku za liječenje, vođenje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, poremećaj imunodeficijencije, poremećaji SŽS, ozljede SŽS, ateroskleroza ili srodni poremećaj, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
An isolated compound of formula I: where: is hydroxy or β-D-xylopyranoside, 
Formulacija izoliranog spoja formule I:, gdje: je hidroksi ili β-d-ksilopiranozid,
The integrated circuit according to claim 1 wherein the applicable RBG size is greater than one. 
Integrirani krug sukladno zahtjevu 1, naznačen time da je broj veličina grupe bloka resursa.
The integrated circuit according to claim 1 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the terminal by units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokalizirani virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
a second layer made of a non-woven fabric having inside a structure formed by fibers of a polypropylene or polyethylene polymer and thermostable elastomers, where the fibers are perforated and impregnated with a finely powdered tourmaline having nanometric size that increases a hydrophilic effect and accelerates a body fluid flow that is going to get in contact, towards the inside of the device; 
drugi sloj izrađen od netkanog prediva koji ima unutarnju strukturu oblikovanu vlaknima iz polipropilena ili polietilen polimera i termostabilnih elastomera, kod čega su vlakna perforirana i impregnirana finim praškastim turmalinom koji ima nanometrijsku veličinu da poveća hidrofilno djelovanje i ubrza tok tjelesnog fluida koji dolazi u kontakt, prema unutrašnjosti uloška;
The use of tourmaline being a finely pulverized dust with nanometric size impregnated in fibers for application in surgical use devices, healing devices, or personal hygiene devices, wherein the fibers are polypropylene and thermostable elastomers fibers and are formed in a non-woven fabric. 
Uporaba turmalina kao fino smrvljenog praha nanometrijske veličine, impregniranog u vlakna, naznačena time, da se u vlaknima primjenjuje u ulošcima za kiruršku primjenu, u ulošcima za zacjeljivanje, ili u ulošcima za osobnu higijenu, kod čega su vlakna polipropilen i vlakna termostabilnih elastomera, a oblikovana su kao netkani materijal.
saturated cycloalkyl group which is cyclohexyl or a pharmaceutically acceptable salt thereof, to combat hair loss. 
zasićene cikloalkil grupe koja je cikloheksil, ili njihove farmaceutski prihvatljive soli, za borbu protiv gubitka kose.
saturated cycloalkyl group which is cyclohexyl; or a pharmaceutically acceptable salt thereof, is formulated with excipients suitable for topical administration on the scalp. 
zasićene cikloalkil grupe koja je cikloheksil; ili njegova farmaceutski prihvatljiva sol, formulirano s ekscipijensima pogodnim za topikalnu primjenu na kožu glave.
receiving slaughtered fish, 
zaprimanje zaklane ribe,
bringing the fish to an under-cooled state in salt-controlled and temperature-controlled solution in at least one first container (6), where: 
dovođenje ribe u stanje pothlađenosti u otopini s kontroliranom količinom soli i s kontroliranom temperaturom u najmanje jednom prvom kontejneru (6), gdje se:
iii) maintaining the volume of the solution in the at least one container (6) to at least 50% of the total volume of fish and solution, 
održava volumen otopine u najmanje jednom kontejneru (6) do najmanje 50% od ukupnog volumena ribe u otopini,
transferring the fish to a transport/storage container, where the temperature in the transport/storage container is maintained below 0°C characterised in that the step of bringing the fish to an under-cooled state is performed in at least two steps of: 
prijenos ribe u prijevozni/skladišni kontejner, pri čemu se temperatura u prijevoznom/skladišnom kontejneru održava ispod 0°C, naznačen time, da se korak dovođenja ribe u stanje pothlađenosti, izvodi u najmanje dva koraka kako slijedi:
transferring the fish to a second salt-controlled and temperature controlled solution having a salt concentration in the range from 1 to 20% and a temperature in the range from -1 to -12°C, where the salt concentration and set temperatures of the salt-controlled and temperature controlled solution brings the homogenous temperature of the fish to -0.1 to -3°C. 
prijenos ribe u drugu otopinu s kontroliranom količinom soli i s kontroliranom temperaturom, koja ima koncentraciju soli u rasponu od 1 do 20% i temperaturu u rasponu od -1 do -12°C, pri čemu koncentracija soli i postavljene temperature u otopini s kontroliranom količinom soli i s kontroliranom temperaturom, dovodi homogenu temperaturu ribe na -0,1 do -3°C.